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Research in context 
Evidence before this study 
There is limited literature available on the prevalence and impact of comorbidities on mortality 
and other disease-related outcomes in bronchiectasis. 
Added value of this study 
In this study, we have confirmed that patients with bronchiectasis are frequently afflicted by 
comorbidities which may drive disease, many of which confer an independent risk of death and 
may be missed unless specifically searched for. We have developed a quantitative risk 
stratification tool, the Bronchiectasis Aetiology and Comorbidity Index (BACI) from a large 
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multicentre derivation cohort of 986 bronchiectasis patients with validation in two independent 
cohorts with a median of 5 and 19 years of follow-up. Our data demonstrate that measurements 
of comorbidities as captured by the BACI improve the prognostic accuracy for mortality, when 
used independently, or in conjunction with the Bronchiectasis Severity Index (BSI), to identify 
patients at risk of future mortality, hospitalisations and exacerbations across different healthcare 
systems. The BACI also carries independent prognostic value relating to future disease 
outcomes including future exacerbations, hospitalisation for severe exacerbations and 
Pseudomonas aeruginosa infection. The BACI performs significantly better than any 
comorbidity scores currently available including the Charlson Comorbidity index and a simple 
comorbidity count suggesting that a disease-specific comorbidity score is useful in this patient 
population.  
 
Implications of all the available evidence 
The BACI may be a useful clinical predictive tool, when used independently, or in conjunction 
with the BSI, to risk-stratify patients and assist clinical decision making and personalised 
medicines approaches in bronchiectasis. The identification of “risky” comorbidities that may 
lead to stricter follow up of these patients may provide a practical viewpoint for clinicians 
beyond the BACI score calculation. Future interventions and treatment approaches should 
consider multiple comorbidities in these patients in order to maximise outcome and reduce the 
illness burden associated with this disease. 
 
140 character summary: The Bronchiectasis Aetiology and Comorbidity Index (BACI) 
identifies patients at risk of future mortality, hospitalisations, exacerbations and other 
outcomes. 
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Abstract: (250 words) 
Background: Patients with bronchiectasis often suffer from concurrent comorbidities but their 
nature, prevalence and impact on disease severity and outcome is poorly understood. We aimed 
to evaluate comorbidities in bronchiectasis patients and determine their prognostic value on 
disease severity and mortality. 
Methods: An observational cohort analysis of 986 bronchiectasis patients across four European 
centres was performed for score derivation. Comorbidity diagnoses were based on standardised 
definitions obtained on full review of hard copy and electronic records, prescriptions and 
investigator definitions. Weibull parametric survival analysis was used to model the prediction 
of 5-year mortality to construct the Bronchiectasis Aetiology Comorbidity Index (BACI). We 
tested the BACI as a predictor of outcomes and explored whether the BACI added further 
prognostic information when used alongside the Bronchiectasis Severity Index (BSI). 
Findings: Median number of comorbidities per patient was 4 (IQR 2-6), range 0-20. Thirteen 
comorbidities independently predicting mortality were integrated into the BACI. The overall 
hazard ratio for death conferred by a one point increase in the BACI was 1.18 (1.14-1.23), 
p<0.0001. The BACI predicted 5-year mortality, hospitalisations, exacerbations and health-
related quality of life across all BSI risk strata (p<0.0001). When used in conjunction with the 
BSI, the combined model was superior to either model alone. The BACI was validated in two 
independent international cohorts. 
Interpretation: Multimorbidity is frequent in bronchiectasis and can negatively influence 
survival. The BACI complements the BSI in assessing mortality and disease outcomes in 
patients with bronchiectasis. 
Funding:  1. European Bronchiectasis Network (EMBARC).2. Health Research Board Ireland. 
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Introduction 
Bronchiectasis is a chronic airway disease showing an increasing prevalence over the past decade 
with an associated growing morbidity and mortality worldwide.1 As a complex multi-component 
disease, bronchiectasis is characterised by chronic systemic inflammation that frequently co-exists 
with comorbidities, which may be causative, synergistic, or coincidental, depending on the manner 
in which they interact.2 
In addition to known aetiologies of bronchiectasis, several other diseases may occur at any stage 
of bronchiectasis and are likely major contributors to increased hospitalisations, healthcare 
utilisation and socioeconomic costs.3 These include cardiovascular disorders, gastro-oesophageal 
reflux disease (GORD), psychological illnesses, pulmonary hypertension, cognitive impairment, 
and lung, oesophageal and hematological malignancies.4-12 A few studies have explored 
bronchiectasis-related comorbidities and suggest that, compared with age and sex-matched 
controls, some comorbidities are more likely to coexist with bronchiectasis4-12 with a relevant 
impact on different outcomes, such as exercise capacity,4 exacerbation  frequency,6,8 lung 
function,7,11 health-related quality of life,6,8,9,11 healthcare utilisation,8 and mortality.10,12 Few 
studies have systematically evaluated the prevalence and role of comorbidities in bronchiectasis; 
several were performed in single centres with small patient numbers4-6,10,11 or utilised retrospective 
databases or cross-sectional designs7-9,12 limiting the applicability of their findings. However, none 
have systematically evaluated how comorbidities impact on prognosis in a prospective study. 
It is suggested that individual comorbidities and aetiologies of bronchiectasis, such as chronic 
obstructive pulmonary disease (COPD) and rheumatoid arthritis (RA), confer an increased severity 
and mortality compared to other aetiologies despite targeted treatment of underlying conditions.13,14 
Recent literature has also shown that in approximately 30-40% of patients with bronchiectasis, the 
primary cause of death is attributed to non-respiratory disease.15 However, current guidelines fail 
to provide clear recommendations on how comorbidities should be identified, assessed and treated 
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within the context of bronchiectasis. Neither of the two prognostic scoring indices recently 
developed to estimate mortality in patients with bronchiectasis (the bronchiectasis severity index –
BSI- and the FACED score-see online supplement for calculation of scores) were planned to 
systematically evaluate the prevalence and role of comorbidities.16,17 
In view of this lack of data, we designed a study which aimed to determine not only the prevalence 
of individual comorbidities in bronchiectasis patients but also the strength of association between 
the number and nature of comorbidities and risk of death over time. We further aimed to develop 
a disease-specific comorbidity index and explore if this could provide additional prognostic 
information to that provided by the BSI. 
Our hypothesis was that multiple comorbidities would be a common finding across national 
cohorts, that these would contribute significantly to mortality and that it was practicable to apply a 
standardised assessment to assess the role of comorbidities in the mortality of patients with 
bronchiectasis. 
 
Methods 
Data collection 
This study included data from four databases of prospectively enrolled outpatients with 
bronchiectasis in Dundee (UK), Galway (Ireland), Leuven (Belgium) and Monza (Italy). 
Consecutive patients aged ≥18 years were enrolled on the basis of a radiological diagnosis made 
on high-resolution computed tomography (HRCT) and a clinical history consistent with 
bronchiectasis. Patients with cystic fibrosis or traction bronchiectasis due to pulmonary fibrosis 
were excluded in all four cohorts. Data from each cohort was collected independently following 
individual ethics approval and collated for statistical analysis. Standardised assessment and 
diagnostic work-up according to the 2010 British Thoracic Society (BTS) guidelines was 
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performed at each site as detailed in the online supplement. Enrolment into the study required that 
all variables required to calculate clinical prediction scores and the key relevant outcomes of 
mortality, hospitalisations and exacerbations on follow-up were available. Exacerbations and 
hospitalisations were defined according to BTS guidelines, and mortality, evaluated at the end of 
the 5-year follow-up period, was confirmed in 100% of participants.18 This cohort is entirely 
independent from the cohorts used to derive the BSI or FACED scores.16,17 
 
Comorbidities 
All comorbidity diagnoses were systematically recorded according to standardised definitions and 
were retrospectively obtained on full review of hard copy or electronic records, patients’ 
prescriptions and review of confirmatory tests where available. The 19 conditions included in the 
Charlson Comorbidity Index (CCI) were included in data collection plus any other identified 
comorbidity.19 Conditions that had completely resolved, e.g. pneumonia, were excluded. Objective 
confirmation of diagnoses was sought in each case where possible. Self-reported diagnoses 
consisted of GORD, depression and anxiety as per standard practice internationally. Further details 
of comorbidity assessment are available in the online supplement. 
 
Statistical Analysis and Derivation of Clinical Prediction Tool 
Continuous data are presented as mean and standard deviation (SD) or median and interquartile 
range (IQR) where appropriate, and categorical data as frequencies and percentages. The Mann 
Whitney U and chi-squared test were used for comparison of numerical and categorical data, 
respectively. For comparisons of more than two groups, one-way analysis of variance or the 
Kruskal-Wallis test were used as appropriate. Weibull parametric survival analysis was used to 
model the prediction of 5-year mortality. Three candidate comorbidity scores were considered and 
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compared to the CCI, BSI and FACED scores: (a) The Comorbidity count - a simple sum of the 
number of comorbidities per individual patient; (b) The Bronchiectasis Comorbidity Index (BCI) - 
a weighted comorbidity score without those conditions regarded as potential underlying aetiologies 
of bronchiectasis; (c) The Bronchiectasis Aetiology Comorbidity Index (BACI) - a weighted 
comorbidity score including conditions regarded as underlying aetiologies. 
Based on Peduzzi’s modelling, a maximum of 13 variables could be incorporated into the 
multivariable models in order to comply with statistical norms based on the number of outcomes 
in our cohort.20 Comorbidities with <1% prevalence or those with significant collinearity were 
excluded. Variables were included in the model using a backward stepwise approach requiring a 
p<0.2 for retention in the model. All models were adjusted for age and gender. These variables 
were then formed into prediction tools using the rounded averaged β-coefﬁcient to award “points” 
for each variable as previously described.16 The sum of the points intends to capture the individual 
or combination of diseases affecting each patient. The performance of the resulting models for 
mortality was assessed using the area under the receiver operator characteristic curve (AUC) with 
the exception of the UK validation cohort which had a much longer median follow up of 19 years, 
whereby Kaplan-Meier analysis was performed to avoid favoring fixed effects at the expense of 
modifiable risk factors that may increase short-term risk but not necessarily guarantee long-term 
risk. We subsequently tested the predictive ability of the optimal model to determine future disease 
outcomes using Spearman’s rho correlation and explored if it could add further prognostic 
information when used alongside the BSI and FACED mortality index. Some endpoints, such as 
quality of life, were only available in 2 cohorts (Dundee and Monza). Such analyses were only 
conducted in patients with available data – no imputation or other methods of handling missing 
data were used. For all analyses, p< 0.05 was considered statistically signiﬁcant. All analyses were 
performed using SPSS Version 21 (SPSS, Chicago, IL, USA) for Windows platform and Graph 
Pad Prism Version 5 (Graph Pad Software, Inc. San Diego, CA, USA). The reporting of this study 
conforms to STROBE and TRIPOD recommendations.21 22 
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Validation cohorts 
The derived index was subsequently validated in two independent cohorts. One was a historical 
cohort of patients recruited for the validation of the SGRQ in bronchiectasis.15 This cohort was 
selected as a prospective study with the longest duration of follow-up available in the literature to 
date, where data on comorbidities was systematically collected. The other validation cohort 
consisted of prospectively recruited bronchiectasis patients in Serbia in Eastern Europe, enabling 
further assessment of the generalisability of the score. 
 
Role of the funding source 
The funding source had no role in study design, data collection, analysis or interpretation or in the 
writing of the report. The corresponding and lead senior authors had full access to all of the data 
and the final responsibility to submit for publication." 
 
Results 
Characteristics of the cohort and comorbidities  
The demographic and baseline characteristics of the 986 patients included in the analysis are 
summarised in Table 1 and are consistent with other published series in terms of older age, female 
predominance and bacterial colonisation rates. The cohort consisted primarily of Caucasian 
females with a median FEV1% predicted of 75% (54-95) and a median FEV1/FVC% predicted of 
70% (59-79) demonstrating moderate airflow limitation. The median BSI was 6 (4-10) and all BSI 
tertiles (mild, moderate and severe) were evenly represented. Mortality, n (%) at 1, 2, 3 and 5 years 
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of follow-up were 37 (3.7), 47 (4.8), 85 (8.6) and 122 (12.4), respectively. No patients received 
lung transplantation during follow-up.  
A total of 81 comorbidities were reported in this cohort. The median (IQR) number of 
comorbidities was 4 (2-6) per subject for the whole cohort with a range of 0-20; males had 
significantly more co-morbidities than females, median 4 (2-6) for males and 3 (2-5) for females, 
p=0.005. . The median number of comorbidities was higher for non-survivors compared with 
survivors [6 (4-9) vs 3 (2-5) respectively, p<0.0001. A significant association was also observed 
between the median number of comorbidities and the BSI score (low risk: 3; intermediate risk: 3; 
high risk: 4; p<0.0001). 
The distribution of the most prevalent (>1%) and significant comorbidities is shown in Figure 1. 
There is a heavy tailed distribution, ranging from 34% to less than 1%. 26 comorbidities had a 
significantly higher prevalence in non-survivors compared with survivors (the majority are shown 
here by the presence of asterisks in Figure 1 with full details in Table S1 in the online supplement).  
 
Comorbidity scores 
The Comorbidity Count 
In its simplest form, the comorbidity count, i.e. the sum of the number of comorbidities per patient, 
was significantly associated with mortality, with a hazard ratio (HR) of 1.17, 95% CI 1.12-1.23 on 
univariate analysis, suggesting that an increase of 1 comorbidity in the count equates to a 17% 
increase in mortality. When adjusted for BSI, the HR (95% CI) was still significant at 1.13 (1.08-
1.18). 
The Bronchiectasis Aetiology Comorbidity Index (BACI) 
The comorbidities included in the BACI are shown in Table 2. COPD, connective tissue disease, 
inflammatory bowel disease and asthma were all included in the final model predicting mortality 
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and are recognised aetiologies of bronchiectasis that may be associated with poorer outcomes. 
Overall, the HR (95% CI) for death conferred by a one-point increase in the BACI score was 1.18 
(1.14-1.23), p<0.0001. Interestingly, this is higher than the adjusted HR for the BSI of 1.10 (1.06-
1.14), p<0.0001 suggesting that the BACI has independent prognostic value comparable to the BSI. 
The Bronchiectasis Comorbidity Index (BCI) 
As a sensitivity analysis, we evaluated a model excluding the above conditions thought to be 
associated with bronchiectasis, producing similar results (Table S2 in online supplement). The HR 
for the BCI was comparable at 1.17 (1.12-1.23), confirming the importance of comorbidities in 
bronchiectasis prognosis. 
 
Comparison of comorbidity scores to predict 5-year mortality 
Comparative AUC (95% CI) scores for the BACI and BCI with the widely validated BSI can be 
seen in figure 2(a). The BACI has the highest overall predictive ability in this cohort to predict 5-
year survival with an AUC score of 0.79 (0.75-0.83) versus 0.74 (0.69-0.78) for the BCI, 0.78 
(0.73-0.84) for the BSI and 0.71 (0.66-0.75) for the FACED score, respectively. The CC and CCI 
(figure 2(b)) showed AUC scores of 0.72 (0.67-0.76) and 0.74 (0.69-0.78) respectively, which were 
inferior to the BACI (p=0.0001 on comparing AUC values), suggesting that a specific comorbidity 
index for bronchiectasis is appropriate.  
The BACI performed consistently better than all scores in predicting 2, 3 and 5-year mortality in 
this cohort, with AUC scores of 0.75, 0.76 and 0.79 respectively, indicating that the score works 
similarly for annual prediction as for longer term prediction. 
The AUC was used to identify the level of the BACI with the greatest predictive value for death in 
patients with bronchiectasis. Patients were classified into tertiles designated no high-risk 
comorbidities (for patients with a score of zero, n=402), intermediate risk comorbidities (for 
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patients with >1 and <6 points, n=398) and high-risk comorbidities (for patients with a score ≥ 6 
points, n=186). The relationship between these risk groups and mortality and morbidity are shown 
in Figure 3.  
The sensitivity and specificity values for the BACI, BCI and the BSI are shown in table 3.  
 
The BACI, BSI and mortality 
Comparable with previous studies, the BSI was a significant predictor of death in patients with 
bronchiectasis. To demonstrate the predictive contribution of the BACI to the BSI, Kaplan-Meier 
survival curves of the BACI groups stratified according to BSI severity are shown in Figure 4. All 
between group comparisons were statistically significant at p<0.001. 
 
A prediction model incorporating both the BSI and the BACI was superior to either model alone 
for the prediction of 5-year mortality in this cohort with an AUC (95% CI) of 0.83 (0.79-0.87). 
 
The BACI and other disease outcomes 
Significant correlations of the BACI with a number of baseline demographic variables and 
important clinical outcomes were noted. The BACI correlated with both the BSI and FACED 
disease severity scores as well as lung function, radiological scores, dyspnoea scores, prior 
exacerbations and hospitalisations. Of note, it also predicts subsequent exacerbations and 
hospitalisations on follow-up and is independently correlated with Pseudomonas aeruginosa 
colonisation, offering further predictive potential in the clinical setting and suggesting that co-
morbidities directly influence pulmonary outcomes (Table 4).  
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Independent validation cohorts 
The Serbian validation cohort consisted of 113 patients, mean age 62 years (13) at diagnosis, 70% 
female. 5-year mortality was 17.7%. The AUC for predicting 5 year mortality in the Serbian cohort 
was 0.74 (95% CI 0.63-0.86). The UK validation cohort included 88 patients, mean age (SD) 51 
years (12.1) at enrolment, with 57% female. Mortality at 20 years was 40.9%. The BACI was 
significantly associated with mortality at 20 years, p=0.004 (Kaplan-Meier), (figure 5). 
 
Discussion  
The present study is the first multicentre international observational study to systematically 
describe the prevalence and associations of comorbidities on mortality in patients with 
bronchiectasis. A new disease-specific comorbidity risk index (the BACI) was derived to help 
predict which patients with bronchiectasis are at increased risk of death independently of their 
baseline physiological state. The BACI accurately stratified the risk of mortality and 
hospitalisations whilst demonstrating that comorbidities contribute to exacerbation frequency and 
impaired quality of life.  The BACI may be a useful clinical predictive tool, when used 
independently, or in conjunction with the BSI, to risk-stratify patients and assist clinical decision 
making and personalised medicines approaches in bronchiectasis. 
This is one of the largest cohort studies performed to date in bronchiectasis and is in keeping with 
other derivation studies in bronchiectasis and other comorbidity derivation tools. In bronchiectasis, 
the BSI and FACED consisted of 608 and 397 patients respectively in their derivation cohorts.16,17 
The Charlson Comorbidity Index, which is perhaps one of the most widely utilised comorbidity 
assessment tools worldwide, consisted of 604 patients in their derivation cohort.19 Therefore, our 
sample size of 986 is more than adequate to derive this score. 
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Most respiratory diseases have disease-specific assessment tools, designed to identify patients at 
high risk of complications who may benefit from early treatment intensification. There is 
accumulating evidence that patients with bronchiectasis, similar to COPD, are prone to develop 
other important diseases, over and above what can be expected in an age and sex-matched general 
population, including cardiovascular disease, pulmonary hypertension and lung cancer, among 
others.4,10,12 With bronchiectasis, there is a “double hit” as many patients may already have an 
underlying aetiology that led to the development of bronchiectasis, potentially increasing the 
likelihood of developing further complications. For example, patients with rheumatoid arthritis and 
bronchiectasis may be receiving immunosuppressive treatments that increase the likelihood of 
complications, or patients with COPD-associated bronchiectasis may be at increased risk of lung 
cancer due to synergistic effects of airway inflammation and smoking.23 
Systemic inflammation has been proposed as a potential explanation of the mechanistic pathway 
relating bronchiectasis with its comorbidities, in part due to the ageing process, which is strongly 
associated with an increased likelihood of developing multiple chronic conditions.24 The 
association between biomarkers of systemic inflammation and outcomes in bronchiectasis, 
including comorbidities, has not been well documented. In COPD, studies have demonstrated that 
elevated baseline inflammatory markers are associated with an increased risk of myocardial 
infarction, diabetes mellitus, lung cancer and pneumonia with the “inflamed comorbids” having 
the lowest survival in COPD populations.25 Addressing this knowledge gap may allow us to 
identify pathway-specific treatment targets that could be beneficial in the treatment of multi-
diseased bronchiectasis patients. Statins and macrolides have both been shown in randomised 
controlled trials to modify disease prognosis and improve clinical outcomes in bronchiectasis, 
owing to their anti-inflammatory effects; the development of new selective anti-inflammatory 
agents may hold promise for the future.26,27  
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A total of 81 different comorbidities were identified during the 5-year follow-up of these patients. 
As expected, not all comorbidities were equally prevalent and there were highly varying strengths 
of association with mortality. Healthcare providers are often limited in their assessment of patients 
due to time constraints and high patient numbers, therefore guidance that could identify 
comorbidities at highest risk of worse outcomes could optimise patient care. Our results show that, 
of the 81 comorbidities identified, 26 differed significantly between survivors and non-survivors. 
This is far higher than the 15 identified in the derivation of the CO-morbidity TEst (COTE) in 
COPD.28 The 13 comorbidities associated with the highest risk of death on multivariate analysis 
were incorporated into the BACI. Similar to those in COPD, these could constitute a core of “red 
flag” comorbidities that healthcare providers should pay increased attention to in guiding a targeted 
personalised screening and treatment approach in patients with bronchiectasis.28 Some, such as 
cardiovascular disease, pulmonary hypertension, cognitive impairment, and lung, oesophageal and 
hematological malignancies, are highly consistent with the little information relating to 
comorbidities in bronchiectasis that is currently available.4-7,10-12  However, the increased risk of 
death conferred by iron deficiency anemia, diabetes mellitus and peripheral vascular disease in this 
population is less well described. These findings therefore raise the possibility of a shared common 
biological pathway among these diseases, which requires further exploration. 
Although hypertension, high cholesterol and osteoporosis were in the top five most prevalent 
comorbidities, the direct risk of mortality conferred by these conditions was not significant. 
Whether this is because they are all treatable or they are risk factors for other potentially more 
harmful diseases, such as myocardial infarction, is unclear. However, selected solid tumors, such 
as lung and oesophageal cancer, conferred a significant increased risk of death with prevalence 
rates of 5% vs. 1% and 3.5% vs. 0.5% in non-survivors versus survivors (p=0.004 and p=0.01), 
respectively (Figure S2 in online supplement for breakdown of prevalence of solid tumors). 
Hematological malignancies, including lymphoma and leukemia, were also associated with a 
significantly increased mortality risk in this patient population. These findings have previously 
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been demonstrated in a nationwide cohort study of >53,000 bronchiectasis patients in Taiwan 
compared to >215,000 age and sex-matched controls whereby a 2.5 fold increased risk of lung 
cancer and a 2-fold increased risk of oesophageal and hematological malignancies was 
demonstrated.12 
A novel finding in this study was the relatively high prevalence of peripheral vascular disease (9%) 
and its strong independent association with risk of death, the mechanism of which remains unclear. 
Diabetes and iron deficiency anemia have both been described in COPD, the former possibly linked 
to overuse of inhaled corticosteroids in this patient population but more likely, both support the 
systemic inflammation hypothesis due to repeated infection, inflammation and chronic immune 
activation.25,29 Correction of anaemia could improve symptoms of fatigue and dyspnoea, thereby 
improving patients’ QoL and exercise capacity, reducing hospitalisations and improving overall 
survival. Anxiety and depression have been reported to be highly prevalent among bronchiectasis 
patients correlating with quality of life measures.8,9 In COPD, anxiety is an independent risk factor 
for mortality but no association of depression or anxiety with mortality was identified in this patient 
cohort.28 
This study confirms that patients with bronchiectasis are frequently afflicted by comorbidities 
which may drive disease, many of which confer an independent risk of death and may be missed 
unless specifically searched for. Although the data may be somewhat intuitive, our finding that 
COPD, inflammatory bowel disease, connective tissue diseases and asthma are associated with a 
higher mortality risk may inform decisions about which patients with bronchiectasis should be 
followed up more closely. Health care providers caring for these patients should routinely screen 
for the comorbidities outlined in the BACI because there may be effective interventions or changes 
in management that could reduce the risk of death. Further follow up studies are needed as with the 
development of any score to substantiate its utility, and determine how this score may impact 
clinical practice. It would also be interesting to further explore the relationship between high BACI 
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scores and lung or systemic inflammation in light of the association between higher exacerbations 
and Pseudomonas colonisation in co-morbid patients. 
The BACI is a quantitative risk stratification aetiology and comorbidity index for clinicians and 
researchers to quantify and prioritise comorbidities in bronchiectasis. Our data demonstrate that 
measurements of comorbidities as captured by the BACI improve the prognostic accuracy for 
mortality, particularly when used in conjunction with the BSI.19 The BACI captures diseases not 
included in the CCI and carries independent prognostic value relating to future disease outcomes 
such as future exacerbations, hospitalisations and Pseudomonas colonisation. Combining the BACI 
and BSI equips healthcare workers and researchers to better stratify patients and provides a 
platform for comparative effectiveness research. 
This study has several limitations: firstly, there is the potential for missed or as yet, undiagnosed 
comorbidities. For example, we experienced a somewhat lower prevalence of depression and 
anxiety in our cohort compared with studies that utilised the Hospital Anxiety and Depression 
Score to assess psychological wellbeing. However, in clinical practice, depression and anxiety are 
diagnosed upon history-taking and therefore this should not influence the results of the study. 
Similarly, there is no objective assessment for GORD, as we rely heavily on questionnaires for 
diagnosis in the clinical setting, often only resorting to the gold-standard 24h pH-impedance studies 
in refractory cases due to cost constraints. We may also have underestimated the prevalence of 
other conditions, such as pulmonary hypertension, in patients who had not had an adequate work-
up for the same but who may in fact, still have co-existing disease. There may have been variation 
between diagnostic criteria used in diagnosing comorbidities due to changes in guidelines 
throughout the study time period and variation in clinical practice between primary and secondary 
care and different healthcare institutions. 
Secondly, although a small number of patients in our derivation cohort had undergone transplant 
assessment, none of the patients in our derivation or validation cohorts had received a transplant 
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therefore we are unable to comment on the utility of the score in this patient population.30 
Comorbidity assessment is routine in the assessment of lung transplant candidates in order to 
determine suitability. The BACI score may highlight comorbidities that could negate transplant, 
e.g. in the case of metastatic malignancy, or perhaps delay transplant, e.g. with cases of iron 
deficiency anaemia where additional treatment may be needed beforehand. However, the BACI 
would not be considered in isolation in the assessment of transplant suitability and, as with any 
clinical prediction tool, it needs to be considered in the context of all other available information.  
Thirdly, with regards to our validation cohorts, we were unable to account for potential recruitment 
bias in the younger less co-morbid patients recruited to the original Brompton cohort of 19 years 
follow up compared to the Serbian cohort. Nevertheless, it is reassuring to see that the BACI works 
well in different cohorts among different healthcare systems. 
Finally, our derived score is relatively complex, awarding different points for each comorbidity. 
To aid calculation of the score, an online calculator is accessible at 
http:\\www.bronchiectasisseverity.com. This assigns a total on inputting the relevant data in 
sequential order and can therefore be completed in a very short space of time in the clinical setting. 
The BACI requires validation in developed countries such as the US and developing countries to 
further substantiate its utility, and further studies determining how this score may impact clinical 
practice are now needed. In support of our findings, however, our large representative derivation 
cohort was made up of almost 1000 patients of varying severity across different healthcare systems 
in four European countries, with external validation in two independent cohorts, one with 19-years 
follow-up and one from Eastern Europe, which should make these results generalisable to many 
bronchiectasis clinics worldwide. 
 
Conclusions 
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Comorbidities in bronchiectasis are common and significantly contribute to disease burden and 
mortality. Surprising links with certain comorbidities may provide new insights into the underlying 
pathogenesis of this disease. We have derived a disease-specific bronchiectasis aetiology and 
comorbidity assessment tool for predicting future risk of mortality in bronchiectasis. Greater focus 
is needed to identify, assess and manage comorbidities in bronchiectasis in both clinical and 
research settings. Future interventions and treatment approaches should consider multiple 
comorbidities in these patients in order to maximise outcome and reduce the illness burden 
associated with this disease. 
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Figure legends: 
Figure 1 legend: Comorbidites in order of overall prevalence among survivor and non-survivor 
bronchiectasis patients. The figure also includes those comorbidities with a significantly higher 
prevalence in non-survivors compared with survivors regardless of their absolute prevalence 
(asterisk). Definitions of abbreviations: GORD: Gastro-oesophageal reflux disease; HTN: 
hypertension; COPD: Chronic obstructive pulmonary disease; CTD: Connective tissue disease; 
MI: myocardial infarction; CHF: Chronic heart failure; PVD: Peripheral vascular disease; 
CKD: Chronic kidney disease; CVA: Cerebrovascular attack; RA: Rheumatoid arthritis; 
ABPA: Allergic bronchopulmonary aspergillosis; TB: Tuberculosis; OSA: Obstructive sleep 
apnea. 
 
Figure 2 legend: (a) The performance of the Bronchiectasis Aetiology Comorbidity Index 
(BACI) in relation to the Bronchiectasis Comorbidity Index (BCI) without aetiologies and the 
widely validated Bronchiectasis Severity Index (BSI) using area under the receiver operator 
characteristic curve (AUC) scores. (b) The performance of the BACI in relation to the 
Comorbidity Count and the widely validated Charlson Comorbidity Index (CCI) using area 
under the receiver operator characteristic curve (AUC) scores. 
 
Figure 3 legend: The performance of the Bronchiectasis Aetiology Comorbidity Index (BACI) 
in predicting mortality, hospitalisations, exacerbation frequency and quality of life across all 
risk strata. All between group comparisons for mortality and hospitalisations were statistically 
significant at p<0.001. Between group comparisons for exacerbations were statistically 
significant at p=0.03. Correlation between the BACI and St George’s Respiratory 
Questionnaire (SGRQ) assessing quality of life was statistically significant at p<0.01. 
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Figure 4 legend: Kaplan-Meier survival curves representing survival probability at 5 years. (a) 
Kaplan-Meier survival curve according to the Bronchiectasis Severity Index (BSI) with mild 
(0-4 points), moderate (5-8 points) and severe (≥ 9 points). To demonstrate the predictive 
contribution of the Bronchiectasis Aetiology Comorbidity Index (BACI) to the BSI, the 
survival curves were represented for each BSI tertile (b) mild disease, (c) moderate disease, 
and (d) severe disease. BACI group 1 = score of O, BACI group 2 = score <6, BACI group 3 
= score ≥ 6. Survival is significantly lower in BACI groups 2 and 3 compared to group 1 which 
represents no high risk comorbidities. The gap between groups becomes much more evident as 
disease severity increases. 
 
 
Figure 5 legend:  Validation of the Bronchiectasis Aetiology Comorbidity Index (BACI) in two 
independent cohorts:  (a) Kaplan-Meier survival curves representing survival probability in 
BACI groups at 20 years in UK population, p=0.004; (b) Area under the receiver operator 
characteristic curve (AUC) score of BACI score in the Serbian cohort.
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Comorbidity paper tables 
Table 1: Derivation Cohort Patient Characteristics 
Patient characteristics Derivation Cohort (n=986) 
Demographic variables   
     Age, Years, Median (IQR)  67 (57-74) 
     Female, n (%) 589 (59.7) 
     Body Mass Index, Median (IQR) 24.6 (21.2-27.8) 
     Smokers / Ex-smokers, n (%) 379 (38.4) 
Clinical status   
     MRC, Median (IQR) 2 (1-3) 
     Exacerbations in the previous year, 
Median (IQR) 
2 (1-3) 
     At least one hospitalisation in the 
previous year, n (%) 
224 (22.7) 
Lung function   
     FEV1 % predicted, Median (IQR) 75 (54-95) 
Radiology status   
     Reiff score, Median (IQR) 4 (2-6) 
Microbiological status   
     Pseudomonas colonisation, n (%) 122 (12.4) 
    Other colonisation, n (%) 229 (25.3) 
Disease severity   
     BSI score, Median (IQR) 6 (4-10) 
     BSI 0-4 (mild), n (%) 312 (31.6) 
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     BSI 5-8 (moderate), n (%) 351 (35.6) 
     BSI ≥ 9 (severe), n (%) 323 (32.8) 
Comorbidities   
     No. of comorbidities, Median (IQR) 4 (2-6) 
     Range 0-20 
 
Definition of abbreviations: MRC: Medical Research Council dyspnoea score, FEV1%: forced 
expiratory volume in 1 second % predicted; BSI: Bronchiectasis Severity Index. 
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Table 2: Derivation of the Bronchiectasis Aetiology Comorbidity Index (BACI) and Point 
Allocation 
 
Comorbidity Hazard Ratio 95% CI P value Points 
Metastatic 
malignancy 
6.69 3.53-12.68 <0.0001 12 
Haematological 
malignancy 
2.85  1.17-6.97 0.02 6 
COPD 2.22  1.53-3.23 <0.0001 5 
Cognitive 
impairment 
2.21  0.82-6.01 0.12 5 
Inflammatory 
bowel disease 
2.01 0.75-5.40 0.17 4 
Liver disease 1.94  0.80-4.72 0.14 4 
Connective 
tissue disease 
1.78 1.19-2.68 0.005 3 
Iron deficiency 
anaemia 
1.78 0.80-2.68 0.16 3 
Diabetes 1.76 1.10-2.80 0.02 3 
Asthma 1.65 1.00-2.73 0.050 3 
Pulmonary 
hypertension  
1.58 0.88-2.84 0.12 3 
Peripheral 
vascular disease 
1.50  1.00-2.25 0.052 2 
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Ischaemic heart 
disease 
1.31 0.91-1.89 0.14 2 
 
 
Definition of abbreviations: COPD: Chronic Obstructive Pulmonary Disease.
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Table 3: Sensitivity and specificity values for derived clinical prediction tools 
 
 
 
 
 
 
 
Definition of abbreviations: BACI: Bronchiectasis Aetiology and Comorbidity Index; BCI Bronchiectasis Comorbidity Index; BSI: Bronchiectasis 
Severity Index 
 
 
 
Organisms PLR NLR Sensitivity Specificity PPV NPV 
BACI  
Grp 2 and 3 vs Grp 1 
Grp 3 vs Grp 1 and 2 
 
1.61 (1.47-1.75) 
3.80 (3.01-4.81) 
 
0.26 (0.16-0.42) 
0.54 (0.45-0.66) 
 
88.5 (81.5-93.6) 
53.3 (44.0-62.4) 
 
44.9 (41.6-48.3) 
86.0 (83.5-88.2) 
 
18.5 (15.4-21.9) 
34.9 (28.1-42.3) 
 
96.5 (94.2-98.1) 
92.9 (90.9-94.6)) 
BCI 
Grp 2 and 3 vs Grp 1 
Grp 3 vs Grp 1 and 2 
 
 
1.57 (1.42-1.74) 
 
4.68 (3.27-6.69) 
 
0.35 (0.23-0.53) 
0.73 (0.65-0.83) 
 
 
83.6 (75.8-89.7) 
 
32.0 (23.8-41.0) 
 
 
46.9 (43.5-50.3) 
 
93.2 (91.3-94.8) 
 
 
18.2 (15.1-21.6) 
 
39.8 (30.0-50.2) 
 
 
95.3 (92.8-97.1) 
 
90.7 (88.6-92.5) 
BSI       
Mod/severe vs mild 
Severe vs Mod/mild 
1.37 (1.26-1.48) 
2.18 (1.83-2.59) 
0.31 (0.18-0.52) 
0.53 (0.42-0.67) 
89.3 (82.5-94.2) 
62.3 (53.1) 
34.6 (31.4-37.9) 
71.4 (68.3-74.4) 
16.2 (13.5-19.2) 
23.5 (19.0-28.5) 
95.8 (92.9-97.8) 
93.1 (90.9-94.9) 
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Table 4: Correlation of the BACI with clinical scores and severity indices 
Patient characteristics (n=986) Spearman’s Rho P value 
BSI 0.23 <0.0001 
FACED 0.24 <0.0001 
Age 0.20 <0.0001 
Male gender 0.20 <0.0001 
Smoking history 0.33 <0.0001 
Reiff radiological score 0.08 0.008 
MRC dyspnoea score 0.31 <0.0001 
LTOT 0.23 <0.0001 
Prior exacerbations 0.12 0.0002  
Prior hospitalisations 0.13 <0.0001 
FEV1 % -0.26 <0.0001 
Pseudomonas colonisation 0.078 0.01 
Exacerbations on follow-up 0.11 0.0006 
Hospitalisations on follow-up 0.22 <0.0001 
 
Definition of abbreviations: BSI: Bronchiectasis Severity Index, FACED: Acronym for a 5-
component disease severity score; MRC: Medical Research Council, LTOT: long term oxygen 
therapy, FEV1%: Forced expiratory volume in 1 second % predicted.  
 
 
